173 related articles for article (PubMed ID: 18589219)
1. Can changing antihypertensive administration time alone reduce the risk for CVD in nondipper patients with CKD?
Fukuda M
Am J Kidney Dis; 2008 Jul; 52(1):193; author reply 193-4. PubMed ID: 18589219
[No Abstract] [Full Text] [Related]
2. Changing concepts in the management of hypertension: the role of effective and prompt blood pressure reduction.
Berbari AE; Khayat A; Daouk N; Daouk M
J Med Liban; 2008; 56(4):226-9. PubMed ID: 19115597
[No Abstract] [Full Text] [Related]
3. New-onset diabetes, antihypertensive treatment, and outcome.
Verdecchia P; Angeli F; Reboldi G
Hypertension; 2007 Sep; 50(3):459-60. PubMed ID: 17679646
[No Abstract] [Full Text] [Related]
4. [High dose sartan plus thiazide. Power duo in hypertension].
MMW Fortschr Med; 2003 Feb; 145(6):60. PubMed ID: 12619369
[No Abstract] [Full Text] [Related]
5. Angiotensin-II-receptor inhibitors in pregnancy.
Chung NA; Lip GY; Beevers M; Beevers DG
Lancet; 2001 May; 357(9268):1620-1. PubMed ID: 11386316
[No Abstract] [Full Text] [Related]
6. Cardiovascular disease in chronic kidney disease.
Saran AM; DuBose TD
Ther Adv Cardiovasc Dis; 2008 Dec; 2(6):425-34. PubMed ID: 19124439
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A
Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
[TBL] [Abstract][Full Text] [Related]
8. [Hypertension and renal disease].
Kamper AL; Pedersen EB; Strandgaard S
Ugeskr Laeger; 2009 Jun; 171(25):2109-13. PubMed ID: 19671393
[TBL] [Abstract][Full Text] [Related]
9. Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan.
Kaneshiro Y; Ichihara A; Sakoda M; Kurauchi-Mito A; Kinouchi K; Itoh H
Kidney Blood Press Res; 2009; 32(1):51-8. PubMed ID: 19258723
[TBL] [Abstract][Full Text] [Related]
10. Preclinical cardiovascular abnormalities in patients in early stages of renal disease without nephrotic syndrome.
Esposito P; Palmieri V; Migliaresi P; Pezzullo S; Martino S; Balletta MM
Hypertens Res; 2009 Dec; 32(12):1155-6. PubMed ID: 19851328
[No Abstract] [Full Text] [Related]
11. Re: Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination.
Vivencio B
Curr Med Res Opin; 2009 Sep; 25(9):2267-8; author reply 2268-9. PubMed ID: 19630488
[No Abstract] [Full Text] [Related]
12. Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective.
Ravera M; Noberasco G; Re M; Filippi A; Gallina AM; Weiss U; Cannavò R; Ravera G; Cricelli C; Deferrari G
Nephrol Dial Transplant; 2009 May; 24(5):1528-33. PubMed ID: 19073656
[TBL] [Abstract][Full Text] [Related]
13. [Individual chronotherapy of essential hypertension and compliance of patients with treatment scheme].
Khromtsova OM
Ter Arkh; 2008; 80(9):29-33. PubMed ID: 19555033
[TBL] [Abstract][Full Text] [Related]
14. Japan. Tampered data cast shadow on drug trial.
Normile D
Science; 2013 Jul; 341(6143):223. PubMed ID: 23868992
[No Abstract] [Full Text] [Related]
15. Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial.
Kjeldsen SE; McInnes GT; Mancia G; Hua TA; Julius S; Weber MA; Coca A; Girerd X; Jamerson K; Larochelle P; Macdonald T; Schmieder RE; Anthony Schork M; Viskoper R; Widimsky J; Zanchetti A
Blood Press; 2008; 17(3):170-7. PubMed ID: 18608200
[TBL] [Abstract][Full Text] [Related]
16. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
17. Interesting findings in the VALERIA trial.
Rosa EM; Viecceli C
J Hypertens; 2009 Apr; 27(4):902; author reply 902-3. PubMed ID: 19300116
[No Abstract] [Full Text] [Related]
18. Chronotherapy beyond blood pressure reduction?
Simko F; Paulis L
J Pineal Res; 2008 Sep; 45(2):227-8. PubMed ID: 18318705
[No Abstract] [Full Text] [Related]
19. Renal function in pediatric liver transplantation: a long-term follow-up study.
Harambat J; Ranchin B; Dubourg L; Liutkus A; Hadj-Haïssa A; Rivet C; Boillot O; Lachaux A; Cochat P
Transplantation; 2008 Oct; 86(8):1028-34. PubMed ID: 18946339
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of valsartan for treatment of hypertension: patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study).
Van der Niepen P; Woestenburg A; Brié H; Vancayzeele S; MacDonald K; Denhaerynck K; Lee C; Hermans C; Abraham I
Ann Pharmacother; 2009 May; 43(5):849-61. PubMed ID: 19351876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
